Line 4: |
Line 4: |
| |- | | |- |
| !'''Disease'''!!'''Page Type'''!!'''Author''' | | !'''Disease'''!!'''Page Type'''!!'''Author''' |
− | !'''Date Assigned (Target Page Completion Date)'''!!'''Associate Editor''' | + | !'''Date Assigned to Author (Target Completion Date)'''!!'''Associate Editor''' |
− | !Author Content Pending or Complete (Date Completed) | + | !'''Author Content Pending or Complete (Date Completed)''' |
− | !Editor Reviewed (Date) | + | !'''Date Completed by Author''' |
− | !Notes | + | !'''Editor Reviewed (Date of Last Review)''' |
| + | !'''Notes''' |
| |- | | |- |
| |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera | | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera |
Line 13: |
Line 14: |
| |Fabiola Quintero-Rivera (FQR) | | |Fabiola Quintero-Rivera (FQR) |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 21: |
Line 23: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 29: |
Line 32: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 37: |
Line 41: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 45: |
Line 50: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 53: |
Line 59: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 61: |
Line 68: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 69: |
Line 77: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 74: |
Line 83: |
| |'''''Mastocytosis'''''||'''''Overview'''''|| | | |'''''Mastocytosis'''''||'''''Overview'''''|| |
| | ||FQR | | | ||FQR |
| + | | |
| | | | | |
| | | | | |
Line 83: |
Line 93: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 91: |
Line 102: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 99: |
Line 111: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 106: |
Line 119: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 113: |
Line 127: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 120: |
Line 135: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 127: |
Line 143: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 134: |
Line 151: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 143: |
Line 161: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |NON-WHO ENTITY | | |NON-WHO ENTITY |
Line 152: |
Line 171: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |NON-WHO ENTITY | | |NON-WHO ENTITY |
Line 159: |
Line 179: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 166: |
Line 187: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 173: |
Line 195: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 180: |
Line 203: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 187: |
Line 211: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 194: |
Line 219: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 200: |
Line 226: |
| | | | | |
| |FQR | | |FQR |
| + | | |
| | | | | |
| | | | | |
Line 208: |
Line 235: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 215: |
Line 243: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 222: |
Line 251: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 229: |
Line 259: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 236: |
Line 267: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 243: |
Line 275: |
| |FQR | | |FQR |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 250: |
Line 283: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 257: |
Line 291: |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 262: |
Line 297: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 270: |
Line 306: |
| |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 276: |
Line 313: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 282: |
Line 320: |
| | ||JH / MS | | | ||JH / MS |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 288: |
Line 327: |
| | ||JH / MS | | | ||JH / MS |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 294: |
Line 334: |
| | ||JH / MS | | | ||JH / MS |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 300: |
Line 341: |
| | ||JH / MS | | | ||JH / MS |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 306: |
Line 348: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 312: |
Line 355: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 319: |
Line 363: |
| |JH / MS | | |JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 325: |
Line 370: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 331: |
Line 377: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 337: |
Line 384: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 343: |
Line 391: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 349: |
Line 398: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 355: |
Line 405: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Need permission for figure? Update WHO? | | |Need permission for figure? Update WHO? |
Line 361: |
Line 412: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 367: |
Line 419: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 373: |
Line 426: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Add WHO reference | | |Add WHO reference |
Line 379: |
Line 433: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 385: |
Line 440: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 391: |
Line 447: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 397: |
Line 454: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Check reference format | | |Check reference format |
Line 403: |
Line 461: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 409: |
Line 468: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 415: |
Line 475: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 421: |
Line 482: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 427: |
Line 489: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 433: |
Line 496: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 439: |
Line 503: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 445: |
Line 510: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 451: |
Line 517: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 457: |
Line 524: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 463: |
Line 531: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 469: |
Line 538: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Need permission for figure? | | |Need permission for figure? |
Line 475: |
Line 545: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 481: |
Line 552: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 487: |
Line 559: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 493: |
Line 566: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 499: |
Line 573: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Check reference format | | |Check reference format |
Line 505: |
Line 580: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 511: |
Line 587: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 517: |
Line 594: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Check reference format | | |Check reference format |
Line 523: |
Line 601: |
| | ||JH / MS | | | ||JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 529: |
Line 608: |
| | ||JH / MS | | | ||JH / MS |
| |?? | | |?? |
| + | | |
| | | | | |
| | | | | |
Line 535: |
Line 615: |
| | ||JH / MS | | | ||JH / MS |
| |?? | | |?? |
| + | | |
| | | | | |
| | | | | |
Line 544: |
Line 625: |
| |JH / MS | | |JH / MS |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |NON-WHO ENTITY | | |NON-WHO ENTITY |
Line 553: |
Line 635: |
| |JH / MS | | |JH / MS |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| |NON-WHO ENTITY | | |NON-WHO ENTITY |
Line 562: |
Line 645: |
| |JH / MS | | |JH / MS |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| |NON-WHO ENTITY | | |NON-WHO ENTITY |
Line 567: |
Line 651: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 573: |
Line 658: |
| |'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| | | |'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| |
| | ||Yassmine Akkari (YA) | | | ||Yassmine Akkari (YA) |
| + | | |
| | | | | |
| | | | | |
Line 579: |
Line 665: |
| |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| | | |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 585: |
Line 672: |
| | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease|| | | | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 593: |
Line 681: |
| |YA | | |YA |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 598: |
Line 687: |
| | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| | | | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 604: |
Line 694: |
| | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| | | | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 614: |
Line 705: |
| |YA | | |YA |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 619: |
Line 711: |
| | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| | | | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 625: |
Line 718: |
| | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| | | | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 633: |
Line 727: |
| |YA | | |YA |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 638: |
Line 733: |
| | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| | | | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 644: |
Line 740: |
| | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| | | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 650: |
Line 747: |
| |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| | | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 656: |
Line 754: |
| |Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| | | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 662: |
Line 761: |
| |NK-Lymphoblastic Leukemia/Lymphoma||Disease|| | | |NK-Lymphoblastic Leukemia/Lymphoma||Disease|| |
| | ||YA | | | ||YA |
| + | | |
| | | | | |
| | | | | |
Line 672: |
Line 772: |
| |YA | | |YA |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| |NON-WHO ENTITY | | |NON-WHO ENTITY |
Line 677: |
Line 778: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 683: |
Line 785: |
| |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| | | |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| |
| | ||Snehal Patel (SP) | | | ||Snehal Patel (SP) |
| + | | |
| | | | | |
| | | | | |
Line 691: |
Line 794: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 698: |
Line 802: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 705: |
Line 810: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 712: |
Line 818: |
| |SP | | |SP |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Malini to review | | |Malini to review |
Line 719: |
Line 826: |
| |SP | | |SP |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Malini to review | | |Malini to review |
Line 726: |
Line 834: |
| |SP | | |SP |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Malini to review | | |Malini to review |
Line 733: |
Line 842: |
| |SP | | |SP |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Malini to review | | |Malini to review |
Line 740: |
Line 850: |
| |SP | | |SP |
| |Complete | | |Complete |
| + | | |
| | | | | |
| |Malini to review | | |Malini to review |
Line 747: |
Line 858: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 754: |
Line 866: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 759: |
Line 872: |
| |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| | | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 765: |
Line 879: |
| |'''''Heavy Chain Diseases'''''||'''''Overview'''''|| | | |'''''Heavy Chain Diseases'''''||'''''Overview'''''|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 771: |
Line 886: |
| | Mu Heavy Chain Disease||Disease|| | | | Mu Heavy Chain Disease||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 777: |
Line 893: |
| | Gamma Heavy Chain Disease||Disease|| | | | Gamma Heavy Chain Disease||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 783: |
Line 900: |
| | Alpha Heavy Chain Disease||Disease|| | | | Alpha Heavy Chain Disease||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 791: |
Line 909: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 798: |
Line 917: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 805: |
Line 925: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 812: |
Line 933: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 819: |
Line 941: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 824: |
Line 947: |
| |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| | | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 830: |
Line 954: |
| | Primary Amyloidosis||Disease|| | | | Primary Amyloidosis||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 836: |
Line 961: |
| | Light Chain and Heavy Chain Deposition Disease||Disease|| | | | Light Chain and Heavy Chain Deposition Disease||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 842: |
Line 968: |
| |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| | | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 848: |
Line 975: |
| | POEMS Syndrome||Disease|| | | | POEMS Syndrome||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 854: |
Line 982: |
| | TEMPI Syndrome||Disease|| | | | TEMPI Syndrome||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 862: |
Line 991: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 867: |
Line 997: |
| |Nodal Marginal Zone Lymphoma||Disease|| | | |Nodal Marginal Zone Lymphoma||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 875: |
Line 1,006: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 882: |
Line 1,014: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 889: |
Line 1,022: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 896: |
Line 1,030: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 903: |
Line 1,038: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 910: |
Line 1,046: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 915: |
Line 1,052: |
| |Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| | | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 921: |
Line 1,059: |
| |Primary Cutaneous Follicle Centre Lymphoma||Disease|| | | |Primary Cutaneous Follicle Centre Lymphoma||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 929: |
Line 1,068: |
| |SP | | |SP |
| |PENDING - due 8/15/20 | | |PENDING - due 8/15/20 |
| + | | |
| | | | | |
| | | | | |
Line 936: |
Line 1,076: |
| |SP | | |SP |
| |PENDING - due 8/31/20 | | |PENDING - due 8/31/20 |
| + | | |
| | | | | |
| | | | | |
Line 943: |
Line 1,084: |
| |SP | | |SP |
| |PENDING - due 8/15/20 | | |PENDING - due 8/15/20 |
| + | | |
| | | | | |
| | | | | |
Line 948: |
Line 1,090: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 956: |
Line 1,099: |
| |Greg Corboy (GC) | | |Greg Corboy (GC) |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 961: |
Line 1,105: |
| |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| | | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 967: |
Line 1,112: |
| |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| | | |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 973: |
Line 1,119: |
| |Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| | | |Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 979: |
Line 1,126: |
| |EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | | |EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 985: |
Line 1,133: |
| |EBV-Positive Mucocutaneous Ulcer||Disease|| | | |EBV-Positive Mucocutaneous Ulcer||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 991: |
Line 1,140: |
| |Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease|| | | |Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 997: |
Line 1,147: |
| | Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease|| | | | Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,003: |
Line 1,154: |
| |Lymphomatoid Granulomatosis||Disease|| | | |Lymphomatoid Granulomatosis||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,009: |
Line 1,161: |
| |Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease|| | | |Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,015: |
Line 1,168: |
| |Intravascular Large B-cell Lymphoma||Disease|| | | |Intravascular Large B-cell Lymphoma||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,021: |
Line 1,175: |
| |ALK-Positive Large B-cell Lymphoma||Disease|| | | |ALK-Positive Large B-cell Lymphoma||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,028: |
Line 1,183: |
| | ||GC | | | ||GC |
| |Complete | | |Complete |
| + | | |
| | | | | |
| | | | | |
Line 1,033: |
Line 1,189: |
| |Primary Effusion Lymphoma||Disease|| | | |Primary Effusion Lymphoma||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,039: |
Line 1,196: |
| |'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| | | |'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,045: |
Line 1,203: |
| | Multicentric Castleman Disease||Disease|| | | | Multicentric Castleman Disease||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,051: |
Line 1,210: |
| | HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | | | HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,057: |
Line 1,217: |
| | HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease|| | | | HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,063: |
Line 1,224: |
| |Burkitt Lymphoma||Disease|| | | |Burkitt Lymphoma||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,069: |
Line 1,231: |
| |Burkitt-Like Lymphoma with 11q Aberration||Disease|| | | |Burkitt-Like Lymphoma with 11q Aberration||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,075: |
Line 1,238: |
| |'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| | | |'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,081: |
Line 1,245: |
| | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| | | | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,087: |
Line 1,252: |
| | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | | | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,093: |
Line 1,259: |
| |B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| | | |B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| |
| | ||GC | | | ||GC |
| + | | |
| | | | | |
| | | | | |
Line 1,099: |
Line 1,266: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,105: |
Line 1,273: |
| |'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''|| | | |'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''|| |
| | ||Snehal Patel (SP) | | | ||Snehal Patel (SP) |
| + | | |
| | | | | |
| | | | | |
Line 1,112: |
Line 1,281: |
| | ||SP | | | ||SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,118: |
Line 1,288: |
| | ||SP | | | ||SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,124: |
Line 1,295: |
| | ||SP | | | ||SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,129: |
Line 1,301: |
| |Aggressive NK-cell Leukemia||Disease|| | | |Aggressive NK-cell Leukemia||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,135: |
Line 1,308: |
| |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| | | |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,141: |
Line 1,315: |
| | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease|| | | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,147: |
Line 1,322: |
| | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| | | | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,153: |
Line 1,329: |
| | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| | | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,159: |
Line 1,336: |
| | Severe Mosquito Bite Allergy||Disease|| | | | Severe Mosquito Bite Allergy||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,165: |
Line 1,343: |
| |Adult T-cell Leukemia/Lymphoma||Disease|| | | |Adult T-cell Leukemia/Lymphoma||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,171: |
Line 1,350: |
| |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| | | |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,179: |
Line 1,359: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,186: |
Line 1,367: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,193: |
Line 1,375: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,200: |
Line 1,383: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,207: |
Line 1,391: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,213: |
Line 1,398: |
| | ||SP | | | ||SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,218: |
Line 1,404: |
| |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| | | |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,224: |
Line 1,411: |
| |Mycosis Fungoides||Disease|| | | |Mycosis Fungoides||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,230: |
Line 1,418: |
| |Sézary Syndrome||Disease|| | | |Sézary Syndrome||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,236: |
Line 1,425: |
| |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''|| | | |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,242: |
Line 1,432: |
| | Lymphomatoid Papulosis||Disease|| | | | Lymphomatoid Papulosis||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,248: |
Line 1,439: |
| | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease|| | | | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,254: |
Line 1,446: |
| |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''|| | | |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,260: |
Line 1,453: |
| | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease|| | | | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,266: |
Line 1,460: |
| | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease|| | | | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,272: |
Line 1,467: |
| | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease|| | | | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,278: |
Line 1,474: |
| | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease|| | | | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,284: |
Line 1,481: |
| |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | | |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,290: |
Line 1,488: |
| |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| | | |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,298: |
Line 1,497: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,305: |
Line 1,505: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,310: |
Line 1,511: |
| | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease|| | | | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease|| |
| | ||SP | | | ||SP |
| + | | |
| | | | | |
| | | | | |
Line 1,318: |
Line 1,520: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,325: |
Line 1,528: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,332: |
Line 1,536: |
| |SP | | |SP |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,337: |
Line 1,542: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,343: |
Line 1,549: |
| |'''''Hodgkin Lymphomas'''''||'''''Overview'''''|| | | |'''''Hodgkin Lymphomas'''''||'''''Overview'''''|| |
| | ||Associate Editor?? | | | ||Associate Editor?? |
| + | | |
| | | | | |
| | | | | |
Line 1,349: |
Line 1,556: |
| |Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease|| | | |Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,355: |
Line 1,563: |
| |'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''|| | | |'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,361: |
Line 1,570: |
| | Nodular Sclerosis Classic Hodgkin Lymphoma||Disease|| | | | Nodular Sclerosis Classic Hodgkin Lymphoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,367: |
Line 1,577: |
| | Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease|| | | | Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,373: |
Line 1,584: |
| | Mixed Cellularity Classic Hodgkin Lymphoma||Disease|| | | | Mixed Cellularity Classic Hodgkin Lymphoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,379: |
Line 1,591: |
| | Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease|| | | | Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,385: |
Line 1,598: |
| |'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| | | |'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,391: |
Line 1,605: |
| |Lymphomas Associated with HIV Infection||Disease|| | | |Lymphomas Associated with HIV Infection||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,397: |
Line 1,612: |
| |'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''|| | | |'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,403: |
Line 1,619: |
| | Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease|| | | | Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,413: |
Line 1,630: |
| | | | | |
| |PENDING | | |PENDING |
| + | | |
| | | | | |
| | | | | |
Line 1,418: |
Line 1,636: |
| |''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''|| | | |''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,424: |
Line 1,643: |
| | Monomorphic B-cell PTLD||Disease|| | | | Monomorphic B-cell PTLD||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,430: |
Line 1,650: |
| | Monomorphic T/NK-cell PTLD||Disease|| | | | Monomorphic T/NK-cell PTLD||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,436: |
Line 1,657: |
| | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease|| | | | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,442: |
Line 1,664: |
| |Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease|| | | |Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,448: |
Line 1,671: |
| |'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''|| | | |'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,454: |
Line 1,678: |
| |Histiocytic Sarcoma||Disease|| | | |Histiocytic Sarcoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,460: |
Line 1,685: |
| |'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''|| | | |'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,466: |
Line 1,692: |
| | Langerhans Cell Histiocytosis||Disease|| | | | Langerhans Cell Histiocytosis||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,472: |
Line 1,699: |
| | Langerhans Cell Sarcoma||Disease|| | | | Langerhans Cell Sarcoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,478: |
Line 1,706: |
| |Indeterminate Dendritic Cell Tumour||Disease|| | | |Indeterminate Dendritic Cell Tumour||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,484: |
Line 1,713: |
| |Interdigitating Dendritic Cell Sarcoma||Disease|| | | |Interdigitating Dendritic Cell Sarcoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,490: |
Line 1,720: |
| |Follicular Dendritic Cell Sarcoma||Disease|| | | |Follicular Dendritic Cell Sarcoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,496: |
Line 1,727: |
| | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| | | | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,502: |
Line 1,734: |
| |Fibroblastic Reticular Cell Tumor||Disease|| | | |Fibroblastic Reticular Cell Tumor||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,508: |
Line 1,741: |
| |Disseminated Juvenile Xanthogranuloma||Disease|| | | |Disseminated Juvenile Xanthogranuloma||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,514: |
Line 1,748: |
| |Erdheim-Chester Disease||Disease|| | | |Erdheim-Chester Disease||Disease|| |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,520: |
Line 1,755: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,526: |
Line 1,762: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,532: |
Line 1,769: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,538: |
Line 1,776: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,544: |
Line 1,783: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,550: |
Line 1,790: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,556: |
Line 1,797: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,562: |
Line 1,804: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,568: |
Line 1,811: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,574: |
Line 1,818: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,580: |
Line 1,825: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,586: |
Line 1,832: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,592: |
Line 1,839: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,598: |
Line 1,846: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,604: |
Line 1,853: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,610: |
Line 1,860: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,616: |
Line 1,867: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,622: |
Line 1,874: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,628: |
Line 1,881: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |
Line 1,634: |
Line 1,888: |
| | || || | | | || || |
| | || | | | || |
| + | | |
| | | | | |
| | | | | |